Personalized in-silico drug response prediction based on the genetic landscape of muscle-invasive bladder cancer
Krentel, F.; Singer, F.; Rosano Gonzalez, L.; Gibb, E. A.; Liu, Y.; Davicioni, E.; Keller, N.; Stekhoven, D.; Kruithof-De Julio, M.; Seiler, R.
Show abstract
In bladder cancer (BLCA) there are, to date, no reliable diagnostics available to predict the potential benefit of a therapeutic approach. The extraordinarily high molecular heterogeneity of BLCA might explain its wide range of therapy responses to empiric treatments. To better stratify patients for treatment response, we present a highly automated workflow for in-silico drug response prediction based on a tumors individual multi-omic profile. Within the TCGA-BLCA cohort, the algorithm identified a panel of 21 genes and 72 drugs, that suggested personalized treatment for 94,7% of patients - including five genes not yet reported as biomarkers for clinical testing in BLCA. The automated predictions were complemented by manually curated data, thus allowing for accurate sensitivity- or resistance-directed drug response predictions. Manual curation revealed pitfalls of current, and potential of future drug-gene interaction databases. Functional testing in patient derived models and/or clinical trials are next steps to validate our in-silico drug predictions.
Matching journals
The top 14 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma 94%
- Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers 92%
- A three gene signature predicts response to selinexor in multiple myeloma 92%
Similar papers in this journal
Similar papers in this journal
- Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations 93%
- Genome-wide associations spanning 194 in-hospital drug dosage change phenotypes highlight diverse genetic backgrounds in concurrent drug therapy 92%
- Drug repositoning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs. 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.